We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Enhancing Intraoperative Margin Assessment in Early-Stage Breast Cancer with Specimen PET-CT Imaging: Insights from the BrIMA Trial

MedXY Editorial Team•Jul 15, 2026•news
breast cancerBreast-Conserving SurgeryIntraoperative Margin AssessmentPET-CT Imaging

Highlight

  • Specimen PET-CT imaging significantly improved intraoperative detection of positive margins in early-stage breast cancer surgeries.
  • Success rates for achieving negative invasive ductal carcinoma margins increased to 95.2% with specimen PET-CT versus 83.3% without intraoperative assessment.
  • Implementation of this imaging approach could reduce re-excision rates, thereby lowering patient morbidity and healthcare costs.
  • Multicenter European trial confirms feasibility and clinical utility of low-dose 18F-FDG PET-CT imaging integrated into surgical workflow.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Proteomic and Metabolomic Insights into Cardiac Remodeling in Breast Cancer Patients Undergoing Cardiotoxic TherapyThis study identifies novel proteomic and metabolomic biomarkers linked to cardiac dysfunction and remodeling in breast cancer patients treated with cardiotoxic therapies, revealing potential pathways for early detection and intervention.Sep 19, 2026Meta-Analysis Shows Immediate Lymphatic Reconstruction Cuts Lymphedema Risk After Axillary DissectionA new meta-analysis of 30 studies indicates that immediate lymphatic reconstruction (ILR) during axillary lymph node dissection for breast cancer is associated with a 63% reduction in the risk of developing lymphedema, though study heterogeneity highlights the need for standardized diagnostic criteria.Jul 24, 2026Cardiac Risk After Heart-Sparing Breast Radiotherapy: Emphasis on Left Anterior Descending Artery Dose MetricsEmerging evidence indicates that radiation dose to the left anterior descending coronary artery better predicts cardiac events than whole-heart dose in breast radiotherapy, emphasizing the importance of LAD-based planning to reduce long-terJul 2, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women
In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.
Jun 19, 2026
GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study SuggestsA large real-world study found GLP-1 receptor agonists were associated with better survival and lower locoregional recurrence than bariatric surgery in postmenopausal women with obesity and breast cancer.Aug 18, 2026
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical TrialAdding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.Aug 18, 2026